» Articles » PMID: 25388215

Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma

Overview
Journal Clin Transl Sci
Date 2014 Nov 13
PMID 25388215
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Epigenetic influences, such as DNA methylation, histone acetylation, and up-regulation/down-regulation of genes by microRNAs, change the genetic makeup of an individual without affecting DNA base-pair sequences. Indeed, epigenetic changes play an integral role in the progression from normal esophageal mucosa to Barrett's esophagus to esophageal adenocarcinoma via dysplasia-metaplasia-neoplasia sequence. Many genes involved in esophageal adenocarcinoma display hypermethylation, leading to their down-regulation. The classes of these genes include cell cycle control, DNA and growth factor repair, tumor suppressors, antimetastasis, Wnt-related genes, and proapoptotic genes. Histone acetylation in the pathophysiology of esophageal diseases has not been thoroughly investigated, and its critical role in the development of esophageal adenocarcinoma is less defined. Many microRNAs have been associated with the development of Barrett's esophagus and esophageal adenocarcinoma. Here, we critically addressed the specific steps most closely influenced by microRNAs in the progression from Barrett's esophagus to esophageal adenocarcinoma. However, microRNAs can target up to hundreds of genes, making it difficult to correlate directly with a given phenotype of the disease. Esophageal adenocarcinoma progressing from premalignant condition of Barrett's esophagus carries an extremely poor prognosis. Risk stratification for patients based on their epigenetic profiles may be useful in providing more targeted and directed treatment to patients.

Citing Articles

Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception.

Tovar Perez J, Zhang S, Hodgeman W, Kapoor S, Rajendran P, Kobayashi K Clin Epigenetics. 2024; 16(1):83.

PMID: 38915093 PMC: 11197381. DOI: 10.1186/s13148-024-01698-8.


Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.

Li S, Hoefnagel S, Krishnadath K Cancers (Basel). 2023; 15(22).

PMID: 38001670 PMC: 10670638. DOI: 10.3390/cancers15225410.


Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers.

Rai V, Abdo J, Agrawal D Int J Mol Sci. 2023; 24(4).

PMID: 36834728 PMC: 9968115. DOI: 10.3390/ijms24043316.


Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.

Mittal S, Abdo J, Adrien M, Bayu B, Kline J, Sullivan M J Gastrointest Oncol. 2021; 12(4):1197-1214.

PMID: 34532080 PMC: 8421895. DOI: 10.21037/jgo-21-117.


Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers.

Barsouk A, Rawla P, Hadjinicolaou A, Aluru J, Barsouk A Med Sci (Basel). 2019; 7(10).

PMID: 31561465 PMC: 6836115. DOI: 10.3390/medsci7100100.


References
1.
Hong J, Li D, Wands J, Souza R, Cao W . Role of NADPH oxidase NOX5-S, NF-κB, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells. Am J Physiol Cell Physiol. 2013; 305(10):C1069-79. PMC: 3840198. DOI: 10.1152/ajpcell.00080.2013. View

2.
Wild C, Hardie L . Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003; 3(9):676-84. DOI: 10.1038/nrc1166. View

3.
Li J, Ying J, Wang X, Wang Z, Tao Q, Li L . Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma. Chin J Cancer. 2012; 32(1):3-11. PMC: 3845589. DOI: 10.5732/cjc.011.10381. View

4.
Fang Y, Chen X, Bajpai M, Verma A, Das K, Souza R . Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. Ann N Y Acad Sci. 2013; 1300:187-199. DOI: 10.1111/nyas.12249. View

5.
Baba Y, Watanabe M, Baba H . Review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg Today. 2013; 43(12):1355-64. DOI: 10.1007/s00595-012-0451-y. View